Is TRIAL Holdings (TSE:141A) Undervalued Following Its Preliminary Sales Update?

TRIAL Holdings (TSE:141A) drew investor attention after reporting preliminary sales figures for June 2026, with comparable store sales at 101.6% year-over-year and all store sales at 108.5% year-over-year.

See our latest analysis for TRIAL Holdings.

At a share price of ¥3,015.0, TRIAL Holdings has a 1 month share price return of 9.84%, yet the share price is down 33.37% over the past 3 months and 4.74% year to date. However, the 1 year total shareholder return of 25.63% points to stronger longer term momentum and a reassessment of the company following its full year sales update.

If TRIAL Holdings’ recent sales figures have you reviewing the retail space, it can help to widen the lens and check stocks in other areas too. One place to start is a curated list of 11 top founder-led companies

TRIAL Holdings’ recent rebound and solid full year sales figures set up a simple tension: has the share price already priced in the good news, or does the current valuation still leave more upside than downside risk?

Preferred P/E of 39.8x: Is it justified?

For TRIAL Holdings, the current picture mixes a relatively high P/E multiple with signals that the stock may still be trading below some valuation estimates.

The preferred multiple here is the P/E ratio, which compares the current share price to earnings per share. At 39.8x, investors are paying almost forty times recent earnings for TRIAL Holdings, a level that often reflects expectations of stronger profit growth rather than a mature, low growth profile.

That expectation is echoed in the forecasts, with earnings projected to grow 28.6% per year and revenue forecast at 8.2% per year, ahead of the broader JP market on both counts. However, the same data flags that this 39.8x P/E is rich compared both to the estimated fair P/E of 19.6x and to the JP Consumer Retailing industry average of 12.8x, as well as a 20.7x peer average. In other words, the market is currently assigning TRIAL Holdings a premium earnings multiple that is much higher than levels the fair ratio analysis suggests the valuation could gravitate toward.

Explore the SWS fair ratio for TRIAL Holdings

Result: Price-to-Earnings of 39.8x (OVERVALUED)

However, TRIAL Holdings’ premium P/E and recent 3 month share price decline of 33.37% leave the story vulnerable if earnings delivery or sentiment softens.

Find out about the key risks to this TRIAL Holdings narrative.

Another view: TRIAL Holdings through the SWS DCF model

While the 39.8x P/E suggests TRIAL Holdings is expensive, the SWS DCF model points in the opposite direction, with an estimated value of ¥8,788.07 per share versus the current ¥3,015. That gap frames the stock as trading at a large discount. Which signal should carry more weight for you?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out TRIAL Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 17 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With TRIAL Holdings carrying both clear risks and appealing rewards, do not sit on the fence. Stress test the numbers yourself and weigh the trade offs using 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond TRIAL Holdings?

If TRIAL Holdings has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to spot other stocks that fit your investing style.

• Target income potential by reviewing companies offering higher yields and steady histories through the 43 dividend fortresses.
• Zero in on value opportunities by scanning the 17 high quality undervalued stocks that combine quality metrics with more modest pricing.
• Prioritise resilience by filtering for companies in the 52 resilient stocks with low risk scores that score well on risk and financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com